Intracavitary/Interstitial Applicator Plus Distal Parametrial Free Needle Interstitial Brachytherapy in Locally Advanced Cervical Cancer: A Dosimetric Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 8

PMID 33680943

Citations 4

Authors

Hong-Da Qu

Dong-Mei Han

Ning Zhang

Zhuang Mao

Guang-Hui Cheng

Affiliations

Soon will be listed here.

Abstract

Purpose: To explore the dosimetric advantage of combining intracavitary/interstitial applicator with distal parametrial free needle interstitial brachytherapy (IC/IS+ISBT DP) based on MRI for locally advanced cervical cancer.

Methods And Materials: 77 IC/IS+ISBT DP treatment plans were developed for 34 patients with locally advanced cervical cancer from June 2016 to January 2020 in this study. We removed the free needles and devised a new IC/ISBT treatment plan based on the same principle. We then compared the dosimetric differences of D90, D98, V100, V150, V200 for HR-CTV (high-risk clinical target volume), D90 for IR-CTV (Intermediate risk-CTV) and D2cc for OARs (organs at risk) between the two groups of treatment plans for the same patient, and the paired T test was performed in parallel. Further, the dosage differences between the two group plans under different parametrial extension widths (the maximum distance of HR-CTV from the vertical direction of the uterine tandem at coronal position) were compared. The survival rate was calculated using the Kaplan-Meier method. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined by Cox regression method. RTOG/EORTC criteria were used to grade toxicities.

Results: A total of 297 free needles were used, with a weight ratio of 15.8% ± 0.11, and a mean insertion depth of 6.52cm ± 2.8cm. D90, D98, V100 for HR-CTV, and D90 for IR-CTV for IC/IS+ISBT DP were significantly higher than IC/ISBT for which free needles were removed (p<0.05). And the V200 for HR-CTV and D2cc for bladder, rectum and sigmoid were decreased (p<0.05). When the parametrial extension widths were greater than 3cm, the HR-CTV D90 and the D2CC for rectum, bladder and sigmoid colon for IC/IS-ISBT DP were advantageous compared to IC/ISBT (p<0.05). The 2-yr OS, PFS and local control rate (LC) were 82.3, 66.8, and 93.1%, respectively. Parametrial extension widths was the only statistically prognostic factors for PFS (p = 0.002) on univariate analysis. No grade 3 or 4 Treatment-related toxicities were observed.

Conclusion: Our institutional experiences showed that IC/IS+ISBT DP is an effective treatment for cervical cancer patients with distal parametrial extension. IC/IS-ISBT DP had dosage advantage and clinical feasibility in locally advanced cervical cancer with distal parametrial extension when the parametrial extension widths were greater than 3cm.

Citing Articles

The significance of free-hand needles in cervical cancer brachytherapy.

Palmgren J, Seppala J, Jaaskelainen E, Anttila M J Contemp Brachytherapy. 2025; 16(6):443-448.

PMID: 39943973 PMC: 11812140. DOI: 10.5114/jcb.2024.146672.

Brachytherapy for cervical cancer: from intracavitary to interstitial technique.

Yang X, Ren H, Li Z, Fu J Front Oncol. 2024; 14:1442712.

PMID: 39568565 PMC: 11576414. DOI: 10.3389/fonc.2024.1442712.

Dosimetric comparison of intra-cavitary brachytherapy technique with free-hand (intra-cavitary + interstitial) technique in cervical cancer.

Jamadagni S, Ponni Tr A, P R J Contemp Brachytherapy. 2024; 16(1):28-34.

PMID: 38584889 PMC: 10993890. DOI: 10.5114/jcb.2024.135629.

The Montreal split ring applicator: Towards highly adaptive gynecological brachytherapy using 3D-printed biocompatible patient-specific interstitial caps.

Kamio Y, Roy M, Morgan L, Barkati M, Beauchemin M, DeBlois F J Contemp Brachytherapy. 2024; 15(6):453-464.

PMID: 38230395 PMC: 10789156. DOI: 10.5114/jcb.2023.133676.

GammaTile: Comprehensive Review of a Novel Radioactive Intraoperative Seed-Loading Device for the Treatment of Brain Tumors.

Ekhator C, Nwankwo I, Rak E, Homayoonfar A, Fonkem E, Rak R Cureus. 2022; 14(10):e29970.

PMID: 36225241 PMC: 9541893. DOI: 10.7759/cureus.29970.

References

Saitoh J, Ohno T, Sakurai H, Katoh H, Wakatsuki M, Noda S . High-dose-rate interstitial brachytherapy with computed tomography-based treatment planning for patients with locally advanced uterine cervical carcinoma. J Radiat Res. 2011; 52(4):490-5. DOI: 10.1269/jrr.10189. View

Yoshida K, Yamazaki H, Kotsuma T, Takenaka T, Ueda M, Miyake S . Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size?. Brachytherapy. 2015; 15(1):57-64. DOI: 10.1016/j.brachy.2015.10.002. View

Fiorentino A, Laudicella R, Ciurlia E, Annunziata S, Lancellotta V, Mapelli P . Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol. 2019; 139:117-124. DOI: 10.1016/j.critrevonc.2019.03.008. View

Viswanathan A, Erickson B, Gaffney D, Beriwal S, Bhatia S, Lee Burnett 3rd O . Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014; 90(2):320-8. PMC: 4194192. DOI: 10.1016/j.ijrobp.2014.06.005. View

Nomden C, de Leeuw A, Moerland M, Roesink J, Tersteeg R, Jurgenliemk-Schulz I . Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011; 82(4):1424-30. DOI: 10.1016/j.ijrobp.2011.04.044. View

Murakami N, Kobayashi K, Shima S, Tsuchida K, Kashihara T, Tselis N . A hybrid technique of intracavitary and interstitial brachytherapy for locally advanced cervical cancer: initial outcomes of a single-institute experience. BMC Cancer. 2019; 19(1):221. PMC: 6417107. DOI: 10.1186/s12885-019-5430-x. View

Kirisits C, Potter R, Lang S, Dimopoulos J, Wachter-Gerstner N, Georg D . Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005; 62(3):901-11. DOI: 10.1016/j.ijrobp.2005.02.040. View

Tanderup K, Eifel P, Yashar C, Potter R, Grigsby P . Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys. 2014; 88(3):537-9. DOI: 10.1016/j.ijrobp.2013.11.011. View

Fokdal L, Tanderup K, Hokland S, Rohl L, Pedersen E, Nielsen S . Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component. Radiother Oncol. 2013; 107(1):63-8. DOI: 10.1016/j.radonc.2013.01.010. View

10.

Mohamed S, Kallehauge J, Fokdal L, Lindegaard J, Tanderup K . Parametrial boosting in locally advanced cervical cancer: combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy. Brachytherapy. 2014; 14(1):23-8. DOI: 10.1016/j.brachy.2014.09.010. View

11.

Harkenrider M, Surucu M, Harmon G, Mysz M, Shea S, Yacoub J . Early outcomes and impact of a hybrid IC/IS applicator for a new MRI-based cervical brachytherapy program. Brachytherapy. 2017; 17(1):187-193. DOI: 10.1016/j.brachy.2017.09.010. View

12.

Kovacs G, Tagliaferri L, Valentini V . Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy. 2018; 9(6):497-498. PMC: 5808000. DOI: 10.5114/jcb.2017.72603. View

13.

Rose P, Bundy B, Watkins E, Thigpen J, Deppe G, Maiman M . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15):1144-53. DOI: 10.1056/NEJM199904153401502. View

14.

Levitchi M, Charra-Brunaud C, Quetin P, Haie-Meder C, Kerr C, Castelain B . Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy. Radiother Oncol. 2012; 103(3):314-21. DOI: 10.1016/j.radonc.2012.04.008. View

15.

Zhao Z, Zhang N, Liu Y, Wu N, Mao Z, Yang W . Analysis of clinical utilization of ring applicator for combined intracavitary/interstitial image-guided brachytherapy treatment in Chinese patients with locally advanced cervical cancer. J Contemp Brachytherapy. 2020; 12(3):252-259. PMC: 7366014. DOI: 10.5114/jcb.2020.96866. View

16.

Lindegaard J, Tanderup K . Counterpoint: Time to retire the parametrial boost. Brachytherapy. 2012; 11(2):80-3. DOI: 10.1016/j.brachy.2012.01.004. View

17.

Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

18.

Hsu I, Speight J, Hai J, Vigneault E, Phillips T, Pouliot J . A comparison between tandem and ovoids and interstitial gynecologic template brachytherapy dosimetry using a hypothetical computer model. Int J Radiat Oncol Biol Phys. 2002; 52(2):538-43. DOI: 10.1016/s0360-3016(01)02691-8. View

19.

Dang Y, Li P, Li J, Bai F, Zhang Y, Mu Y . The Efficacy and Late Toxicities of Computed Tomography-based Brachytherapy with Intracavitary and Interstitial Technique in Advanced Cervical Cancer. J Cancer. 2018; 9(9):1635-1641. PMC: 5950593. DOI: 10.7150/jca.23974. View

20.

Potter R, Dimopoulos J, Georg P, Lang S, Waldhausl C, Wachter-Gerstner N . Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007; 83(2):148-55. DOI: 10.1016/j.radonc.2007.04.012. View